Searched for
PHARMACEUTICAL MANUFACTURING UNITS
These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsIt is probably time to be bullish as an investor. But remember two things. One: Valuations are still not cheap. Two: Because it is over and...- Indian pharma firms gear up to supply key cancer drug to USIndian drugmakers are stepping up to help the US combat a critical shortage of ifosfamide injection, a vital chemotherapy drug. Leading com...
- For investors who focus on the long term: 5 mid-cap stocks from different sectors with upside potential up to 28%When prices fall, caution comes naturally. Investors hesitate, portfolios are reviewed less often, and even optimists become careful. But w...
- India's pharma supply chain remains 65 per cent dependent on China for critical inputs: NITI AayogIndia's pharmaceutical sector, despite being the "pharmacy of the world," faces significant reliance on China for raw materials, with nearl...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 24%When business updates start to come in or when some FMCG or auto companies indicate that things are not all good in the rural space, we may...
- NFO Alert: Tata Mutual Fund announces launch of Tata Multi-sector Passive FoFTata Mutual Fund has launched the Tata Multi-sector Passive FoF, an open-ended scheme investing in passive equity funds across various sect...
- Stocks in news: Sun Pharma, Tech Mahindra, Tata Motors, Voltas, ONGCIndian markets saw a dip on Friday, with IT stocks leading the decline. Analysts suggest profit-taking occurred near the 24,150 mark. Despi...
- These large- mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...
- India’s trade strategy: Moving beyond FTAsCurrently, India’s FTA utilisation rate hovers around 25% compared to 70-80% in developed economies.
- HealthQuad raises Rs 550 crore, eyes Rs 1,700 crore fundHealthQuad has secured Rs 550 crore for its third fund. The venture capital firm aims to raise Rs 1,700 crore to back early-growth companie...
- Odisha govt approves 20 mega investment proposals worth Rs 76,612 croreOdisha's government has approved 20 mega investment proposals totaling Rs 76,612 crore, projected to create over 50,000 jobs. These signifi...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 27%As the market seems to be in comeback mode, it helps to be aware that the best (and probably biggest) wealth creator of the last couple of ...
- Indian pharma leaving generics era behind, but the Street hasn't caught up yet: Nandan KulkarniIndian pharma is shifting from generics to innovation. This transformation, extending to 2035, is creating significant new opportunities. C...
- Global drugmakers rush to boost US presence as tariff threat loomsGlobal drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Com...
- IPO Calendar: Two companies to launch public offers in a quiet week for the primary marketThe IPO market will see limited activity next week, with only two SME issues, Liotech Industries and Leapfrog Engineering, opening on June ...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 26%On Thursday evening, US President Trump said he would “hit Iran hard tonight”. Then, as the world waited with bated breath, came the announ...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 27%, according to analystsWe are in a phase in the US-Israel-Iran war where statements are made, then retracted. And, in a matter of just 48 hours, they are made all...
- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...
- Govt outlines next phase of pharma growthThe government highlighted its achievements, reforms, and policy initiatives, aiming to boost exports from $31 billion to $50 billion by 20...
- Over 60% of pharma MSMEs yet to comply with updated manufacturing normsPharma industry officials say the revised Schedule M regulations could require Rs 10-15 crore per facility in upgrades, while talent shorta...
Load More
